93 149

Cited 0 times in

Cardiovascular and cerebrovascular-associated mortality in patients with preceding bronchiectasis exacerbation

Authors
 Sang Chul Lee  ;  Kang Ju Son  ;  Chang Hoon Han  ;  Seon Cheol Park  ;  Ji Ye Jung 
Citation
 THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, Vol.16 : 17534666221144206, 2022-12 
Journal Title
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE
ISSN
 1753-4658 
Issue Date
2022-12
MeSH
Bronchiectasis* / diagnosis ; Bronchiectasis* / epidemiology ; Disease Progression ; Hospitalization ; Humans ; Lung ; Proportional Hazards Models ; Retrospective Studies
Keywords
atherosclerotic cardiovascular disease ; atherosclerotic cerebrovascular disease ; bronchiectasis ; exacerbation ; mortality
Abstract
Background: Bronchiectasis is associated with an increased incidence of atherosclerotic cardiovascular disease (ASCaVD) and atherosclerotic cerebrovascular disease (ASCeVD). Its effect on associated mortality is unclear.

Objectives: This study investigated the effects of bronchiectasis exacerbation prior to ASCaVD or ASCeVD events on mortality in patients with bronchiectasis using a large population-based database.

Methods: A retrospective cohort of patients with bronchiectasis who experienced ASCaVD (n = 1066) or ASCeVD (n = 825) was studied for the first time using a nationwide population-based database (National Health Insurance Service-National Sample Cohort, Korea, 2002-2015). We classified each cohort according to the presence of moderate bronchiectasis exacerbation within 1 year before the ASCaVD or ASCeVD event. We evaluated 90-day, 1-year, and all-cause mortalities risk.

Results: Within 1 year before the index ASCaVD or ASCeVD event, 149 (13.9%) and 112 (13.6%) patients with bronchiectasis experienced moderate exacerbation(s), respectively. Mild exacerbations did not different in frequency between the survivors and nonsurvivors. In both cohorts, more nonsurvivors experienced moderate exacerbations than survivors. The odds ratios of 90-day and 1-year mortalities and hazard ratios of all-cause mortalities on experiencing moderate exacerbations were 2.27 [95% confidence interval (CI) = 1.26-4.10], 3.30 (95% CI = 2.03-5.38), and 1.78 (95% CI = 1.35-2.34) in the bronchiectasis-ASCaVD cohort and 1.73 (95% CI = 0.94-3.19), 1.79 (95% CI = 1.07-3.00), and 1.47 (95% CI = 1.10-1.95), in the bronchiectasis-ASCeVD cohort.

Conclusion: Hospitalization or emergency room visit for bronchiectasis exacerbation within 1 year before ASCaVD or ASCeVD is associated with an increased ASCaVD- or ASCeVD-associated mortality.
Files in This Item:
T202300152.pdf Download
DOI
10.1177/17534666221144206
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Jung, Ji Ye(정지예) ORCID logo https://orcid.org/0000-0003-1589-4142
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/192935
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links